Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 9:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 216 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo powder group Clear all
Terminated Phase 2 Interventional Results available

Efficacy, Safety and Tolerability of AG013 in Oral Mucositis Compared to Placebo When Administered Three Times Per Day

NCT03234465
View directory record Official record
Conditions
Oral Mucositis
Interventions
AG013, Placebo
Biological · Other
Lead sponsor
Oragenics, Inc.
Industry
Eligibility
21 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
27
States / cities
Farmington, Connecticut • Newark, Delaware • Orlando, Florida + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 4, 2026, 9:18 AM EDT
Completed Phase 4 Interventional Results available

A 24-Week Study to Evaluate the Safety and Efficacy of ADVAIR DISKUS® Inhaler 250/50mcg Plus SPIRIVA HANDIHALER® Inhaler Versus SPIRIVA HANDIHALER® Inhaler Plus Placebo DISKUS® Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD).

NCT00784550
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium Bromide, Fluticasone Propionate/Salmeterol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 99 Years
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
35
States / cities
Riverside, California • Fort Collins, Colorado • Clearwater, Florida + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2016 · Synced Oct 4, 2026, 9:18 AM EDT
Completed Phase 3 Interventional Results available

A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia

NCT01179217
View directory record Official record
Conditions
Sickle Cell Anemia, Sickle ß0-Thalassemia
Interventions
L-glutamine, Placebo
Drug
Lead sponsor
Emmaus Medical, Inc.
Industry
Eligibility
5 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
31
States / cities
Mobile, Alabama • Phoenix, Arizona • Inglewood, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2020 · Synced Oct 4, 2026, 9:18 AM EDT
Completed Phase 3 Interventional Results available

HZA113091 Efficacy and Safety of Fluticasone Furoate/Vilanterol (GW642444) in Adults and Adolescents

NCT01147848
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone furoate/Vilanterol Inhalation Powder, Fluticasone propionate/salmeterol Inhalation Powder, Placebo (1), Placebo (2)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
810 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
25
States / cities
Huntington Beach, California • Los Angeles, California • Riverside, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Oct 4, 2026, 9:18 AM EDT
Completed Phase 3 Interventional Results available

A Phase IIIb Study to Evaluate the Efficacy of Umeclidinium/Vilanterol (UMEC/VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT02152605
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
UMEC/VI, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
498 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
11
States / cities
Phoenix, Arizona • Upland, California • Clearwater, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2017 · Synced Oct 4, 2026, 9:18 AM EDT
Completed Phase 3 Interventional Results available

A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01879410
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
UMEC/VI Inhalation Powder 62.5/25 mcg via NDPI, FSC Inhalation Powder 250/50 mcg via ACCUHALER/DISKUS, Placebo DISKUS, Placebo NDPI
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
15
States / cities
Tucson, Arizona • Newport Beach, California • Riverside, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Oct 4, 2026, 9:18 AM EDT
Terminated Phase 2 Interventional Results available

Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)

NCT03345407
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Placebo ELLIPTA, Nemiralisib ELLIPTA 50 µg, Nemiralisib ELLIPTA 100 µg, Nemiralisib ELLIPTA 250 µg, Nemiralisib ELLIPTA 500 µg, Nemiralisib ELLIPTA 750 µg, Albuterol (Salbutamol) MDI or nebules, Standard of care therapy
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 80 Years
Enrollment
943 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
21
States / cities
Mobile, Alabama • Colorado Springs, Colorado • Daytona Beach, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2021 · Synced Oct 4, 2026, 9:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of a Dietary Supplement on Exercise Performance in Healthy Older Adults"

NCT01073332
View directory record Official record
Conditions
Excessive Physical Exercise, Unspecified
Interventions
Arginine antioxidant supplements, Placebo
Dietary Supplement
Lead sponsor
University of California, Los Angeles
Other
Eligibility
50 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 8, 2015 · Synced Oct 4, 2026, 9:18 AM EDT
Completed Phase 2 Interventional Results available

Dose Ranging Study Evaluating the Efficacy and Safety of GSK2190915 Administered Once Daily

NCT01147744
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone Propionate 100mcg via ACCUHALER/DISKUS, GSK2190915 100mg, GSK2190915 10mg, GSK2190915 300mg, GSK2190915 30mg, Montelukast 10mg, Placebo GSK2190915 one tablet, Placebo montelukast, Placebo fluticasone propionate via ACCUHALER/DISKUS, Placebo GSK2190915 two tablets
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older · Female only
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
22
States / cities
Birmingham, Alabama • Huntington Beach, California • Newport Beach, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2017 · Synced Oct 4, 2026, 9:18 AM EDT
Withdrawn Phase 2 Interventional

Safety and Efficacy of 4-weeks Treatment of BIBW 2948 BS in Patients With Chronic Obstructive Bronchitis

NCT00726479
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Bronchitis, Chronic
Interventions
BIBW 2948 BS
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
8
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fort Collins, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2014 · Synced Oct 4, 2026, 9:18 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Supplementation of Glutamine and Fish Oil Versus Placebo in Patients With Heart Failure

NCT01534663
View directory record Official record
Conditions
Heart Failure
Interventions
Glutamine and Fish Oil Supplementation, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
35 Years to 80 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Oct 4, 2026, 9:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Antioxidants on Cardiovascular Risk Measures (Spice Study)

NCT00954902
View directory record Official record
Conditions
Cardiovascular, Psychological Stress
Interventions
High Antioxidant Spice Blend, Trier Psychological Stressor, Placebo antioxidant concentrate
Dietary Supplement · Behavioral · Other
Lead sponsor
Penn State University
Other
Eligibility
30 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 25, 2018 · Synced Oct 4, 2026, 9:18 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Assess the Effectiveness and Safety of IPN10200 Over Time in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows

NCT07435428
View directory record Official record
Conditions
Moderate to Severe Glabellar Lines
Interventions
Corabotase, Placebo
Biological
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
1,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
41
States / cities
Los Angeles, California • Newport Beach, California • Pasadena, California + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 4, 2026, 9:18 AM EDT
Completed Not applicable Interventional

Impact of Resistance Training-Protein Supplementation on Lean Muscle Mass in Childhood Cancer Survivors

NCT02501460
View directory record Official record
Conditions
Cancer
Interventions
Educational handouts, Resistance training, Supplementation, Placebo
Other · Dietary Supplement
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
18 Years to 44 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Oct 4, 2026, 9:18 AM EDT
Completed Phase 3 Interventional Results available

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Cervical Dystonia

NCT00407030
View directory record Official record
Conditions
Cervical Dystonia
Interventions
incobotulinumtoxinA (Xeomin) (240 Units), incobotulinumtoxinA (Xeomin) (120 Units), Placebo
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 19, 2013 · Synced Oct 4, 2026, 9:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of Synaquell on Brain Function of Ice Hockey Players

NCT05498818
View directory record Official record
Conditions
Healthy
Interventions
Synaquell, Placebo
Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
13 Years to 19 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 9, 2024 · Synced Oct 4, 2026, 9:18 AM EDT
Completed Not applicable Interventional

Effect of Blueberry Consumption on Metabolic Syndrome & DNA Damage

NCT02075307
View directory record Official record
Conditions
Metabolic Syndrome, Insulin Resistance, DNA Damage
Interventions
Blueberry Powder, Placebo
Dietary Supplement
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
30 Years to 60 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Dec 23, 2020 · Synced Oct 4, 2026, 9:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Prenatal Probiotic Intervention

NCT03240419
View directory record Official record
Conditions
Childhood Obesity, Maternal Obesity During Childbirth, Insulin Resistance, Inflammation
Interventions
Probiotics, Placebo
Dietary Supplement
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Oct 4, 2026, 9:18 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks

NCT01772134
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Umeclidinium bromide 62.5mcg, Umeclidinium bromide 125mcg, Fluticasone propionate 250mcg/Salmeterol 50mcg, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
617 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
13
States / cities
Jasper, Alabama • Clearwater, Florida • Ormond Beach, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2018 · Synced Oct 4, 2026, 9:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Omega-3 and Blueberry Supplementation in Age-Related Cognitive Decline

NCT01746303
View directory record Official record
Conditions
Age-related Memory Disorders, Mood Disorders
Interventions
Omega-3 fatty acid, Blueberry powder, Placebo oil, Placebo powder
Dietary Supplement · Other
Lead sponsor
University of Cincinnati
Other
Eligibility
62 Years to 80 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 27, 2016 · Synced Oct 4, 2026, 9:18 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD)

NCT01089127
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Indacaterol, Salmeterol 50 μg, Placebo to indacaterol, Placebo to salmeterol
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
552 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
69
States / cities
Florence, Alabama • Jasper, Alabama • Phoenix, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2011 · Synced Oct 4, 2026, 9:18 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Gastrointestinal And Metabolic Effects From a Prebiotic, Lifting, and Aerobic iNtervention

NCT05207488
View directory record Official record
Conditions
Overweight and Obesity
Interventions
Fructooligosaccharides (FOS), Exercise, Placebo
Dietary Supplement · Behavioral
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
20 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 10, 2022 · Synced Oct 4, 2026, 9:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Dietary Nitrate and Physiological Aging

NCT02593305
View directory record Official record
Conditions
Aging
Interventions
Super Beets, Super Beets Placebo
Dietary Supplement
Lead sponsor
Darren P Casey
Other
Eligibility
18 Years to 85 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Oct 14, 2019 · Synced Oct 4, 2026, 9:18 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Glycine vs Placebo for the Schizophrenia Prodrome

NCT00291226
View directory record Official record
Conditions
Schizophrenia Prodrome
Interventions
Glycine, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
13 Years to 35 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 2, 2020 · Synced Oct 4, 2026, 9:18 AM EDT